Antagonism of Antiviral and Allogeneic Activity of a Human Public CTL Clonotype by a Single Altered Peptide Ligand: Implications for Allograft Rejection
Lauren K. Ely(Howard Hughes Medical Institute), Scott R. Burrows(Australian National University), Katherine J. Green(The University of Queensland), Craig S. Clements(University of Colorado Anschutz Medical Campus), Travis Beddoe(La Trobe University), Danielle Zernich(The University of Melbourne), Jamie Rossjohn(Institute of Infection and Immunity), Anthony W. Purcell(Discovery Institute), Stephen Bottomley(Monash University), Lars Kjer‐Nielsen(The University of Melbourne), John J. Miles(University of Cambridge), James McCluskey(Peter Doherty Institute)
Cited by 35
Related Papers
More than one reason to rethink the use of peptides in vaccine design
|Nature Reviews Drug Discovery|2007|860
Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells
|The Journal of Experimental Medicine|2013|595
Transcriptional signature in microglia associated with Aβ plaque phagocytosis
|Nature Communications|2021|406